Chronic lymphocytic leukaemia+1
RecruitingStudy of Lisaftoclax Alone or with Drug Combination for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study of Lisaftoclax Alone or with Drug Combination for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Disease:Chronic lymphocytic leukaemiaB-cell small lymphocytic lymphoma
- Substances:AcalabrutinibIbrutinib+3
Hungary- Participants:18–64 years · 65+ years
- Substances:Acalabrutinib
- Sponsor:Ascentage Pharma Group Inc.














